

Whole Blood Panel

Shay Jones, MLS(ASCP)^{CM} BB^{CM}

Carrie Easley, MSTM MLS (ASCP) SBB^{CM}



THE UNIVERSITY OF KANSAS HEALTH SYSTEM



Stormont Vail
Health

Objectives

- Describe the use of whole blood for transfusion
- Discuss patient populations for utilization of whole blood
- Review potential risks of whole blood
- Evaluate financial implications of a whole blood program

Whole Blood Panel Discussion

- How did the conversation about implementation begin?
- Who were your facility champions?
- Was there any pushback?
- What were initial challenges/concerns?
- When did you go live?



Utilization

- What demographics receive LTOWB at your facility?
- What is included in your high-acuity Trauma cooler?



Utilization



5.27.2

If low-titer group O Whole Blood is used, the BB/TS shall have policies, processes, and procedures to define:



1. Low-titer threshold.
2. Use of low-titer group O Whole Blood.
3. Maximum volume/units allowed per event.

Standard 5.15.4 applies.


- What is your facility limit of whole blood units transfused to an unknown type? To a known Type O? To a known non-type O?

Utilization

- KU usage to date:
 - 2024 = 204
 - 2025 = 199



Utilization



- SVH usage to date:
 - 2024 = 26 (go-live in July)
 - 2025 = 60
 - 2026 = 5

Wastage

- Do you struggle with whole blood outdating?
- Who assumes the financial burden of blood component wastage? Transfusion Service? Actual service line?





Future Plans

Receipt of RhD-positive whole blood for life-threatening bleeding in female children: A survey in alloimmunized mothers regarding minimum acceptable survival benefit relative to risk of maternal alloimmunization to anti-D

[Molly R. Sherwood](#) ✉, [Skye Clayton](#), [Christine M. Leeper](#), [Mark Yazer](#), [Kenneth J. Moise Jr.](#), [Marion E. Granger](#), [Philip C. Spinella](#)

It is time to reconsider the risks of transfusing RhD negative females of childbearing potential with RhD positive red blood cells in bleeding emergencies

[Mark H. Yazer](#) ✉, [Meghan Delaney](#), [Heidi Doughty](#), [Nancy M. Dunbar](#), [Arwa Z. Al-Riyami](#), [Darrell J. Triulzi](#), [Jon F. Watchko](#), [Erica M. Wood](#), [Vered Yahalom](#), [Stephen P. Emery](#)

Whole blood transfusion in the management of obstetric hemorrhage: A scoping review

[Justin Lalonde](#), [Pierre-Marc Dion](#), [Abigaël Carpentier](#), [Mikaëlle Chauret](#), [Mohamed S. Eissa](#), [Mark Walker](#), [Risa Shorr](#), [Johnathan Mack](#) ✉

Weighing the risk of hemolytic disease of the newborn versus the benefits of using of RhD-positive blood products in trauma

[Jennifer Andrews](#) ✉, [Cassandra D. Josephson](#), [Pampee Young](#), [Philip C. Spinella](#), [Mark H. Yazer](#)

Low titer Group O whole blood utilization in pediatric trauma resuscitation: A National Survey

[Dana Meshkin](#), [Mark H. Yazer](#), [Nancy M. Dunbar](#), [Philip C. Spinella](#), [Christine M. Leeper](#) ✉

QUESTIONS?

